research use only

Orforglipron (LY3502970) GLP-1R Agonist

Cat.No.S9852

Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both.
Jump to

Quality Control

Batch: S985201 DMSO]100 mg/mL]false]Water]Insoluble]false]Ethanol]Insoluble]false Purity: 99.00%
99.00

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (113.25 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : Insoluble

Ethanol : Insoluble

Molarity Calculator

Mass Concentration Volume Molecular Weight
Dilution Calculator Molecular Weight Calculator

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg
g
μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO
%
% Tween 80
% ddH2O
% DMSO
+
%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight 882.96 Formula

C48H48F2N10O5

Storage (From the date of receipt)
CAS No. 2212020-52-3 Download SDF Storage of Stock Solutions

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC50/Ki
GLP-1 receptor
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-24)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT07241390 RECRUITING
Atherosclerosis Cardiovascular Disease; Chronic Kidney Disease
Eli Lilly and Company
2025-12-01 PHASE3
NCT07729332 NOT_YET_RECRUITING
Obesity
Massachusetts General Hospital
2026-11-01 PHASE4
NCT07668336 NOT_YET_RECRUITING
Diabetes Mellitus, Type 2
Eli Lilly and Company
2026-09 PHASE3
NCT07739537 NOT_YET_RECRUITING
Diabete Type 2; Pharmacogenomic Drug Interaction
Massachusetts General Hospital
2026-10-01 PHASE4
NCT07794579 NOT_YET_RECRUITING
Overweight; Prediabetic State; Prehypertension; Obesity, Abdominal
Eli Lilly and Company
2026-09 PHASE3
NCT07223593 RECRUITING
Peripheral Arterial Disease
Eli Lilly and Company
2025-10-31 PHASE3

Read more about Clinical Trials

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.